GlassScriptPhysician profile
Edwin Jonattan Vences
NPI 1376196345
$8,551.53
in general payments reported to CMS, 2019-2025
41 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $800 · 2023: $1,178 · 2024: $3,651 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,611 · Travel and Lodging: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,611.44 |
| Travel and Lodging | $1,140.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,701.99 | 2023-2025 | Inspire |
| Abbvie INC. | $1,004.59 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $616.22 | 2022-2025 | |
| Eisai INC. | $512.24 | 2022-2025 | |
| Emd Serono, INC. | $395.05 | 2022-2025 | Mavenclad |
| Lilly USA, LLC | $304.32 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $258.88 | 2022 | |
| Pfizer INC. | $254.69 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $212.15 | 2022-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $207.55 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $205.86 | 2023-2025 | Ultomiris |
| Axsome Therapeutics, INC. | $179.80 | 2023-2025 | Symbravo, Sunosi |
| Acadia Pharmaceuticals INC | $162.94 | 2023-2025 | Nuplazid |
| Tg Therapeutics, INC. | $153.31 | 2025 | |
| Ucb, INC. | $125.65 | 2024-2025 | Rystiggo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $115.18 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $100.56 | 2023-2025 | Hyqvia, Gammagard |
| Merz Pharmaceuticals, LLC | $90.71 | 2023-2025 | Xeomin, Inbrija |
| Otsuka America Pharmaceutical, INC. | $87.37 | 2023-2025 | Rexulti, Nuedexta |
| Harmony Biosciences LLC | $77.94 | 2023-2025 | Wakix |
| Aucta Pharmaceuticals, INC. | $71.42 | 2024-2025 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $71.07 | 2024-2025 | Horizant |
| Biogen, INC. | $67.30 | 2023-2024 | Vumerity, Tysabri |
| Genzyme Corporation | $63.46 | 2022-2025 | |
| Sk Life Science, INC. | $62.51 | 2022-2023 | |
| Argenx US, INC. | $58.94 | 2022-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $54.36 | 2022-2025 | Vyepti |
| Grifols USA, LLC | $52.82 | 2024-2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $35.57 | 2025 | Brekiya, Crexont |
| Amgen INC. | $31.87 | 2022 | |
| Jazz Pharmaceuticals INC. | $30.45 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $22.62 | 2024 | |
| Impel Pharmaceuticals LLC | $22.36 | 2025 | Trudhesa |
| Cycle Pharmaceuticals INC | $20.96 | 2025 | Tascenso Odt |
| Medtronic, INC. | $20.12 | 2022 | |
| Mdd US Operations, LLC | $19.81 | 2023 | Gocovri |
| Vanda Pharmaceuticals INC. | $19.13 | 2024 | Ponvory |
| Zoll Respicardia, INC. | $17.27 | 2024 | Remede System |
| Astrazeneca Pharmaceuticals LP | $17.21 | 2022 | |
| Avion Pharmaceuticals | $14.85 | 2022 | |
| Life Molecular Imaging LTD | $10.43 | 2023 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Vences listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.